| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Invivyd Inc. | VYD2311 - (LIBERTY) | COVID vaccine | Phase 3 | Ongoing | Intravenous | COVID-19 |
| Invivyd Inc. | PEMGARDA (VYD222 (pemivibart)) - (CANOPY) | COVID-19 Prevention | Phase 3 | Data Released | Intravenous | COVID-19 |
| Invivyd Inc. | ADG20 - (STAMP) | COVID-19 (treatment) | NDA Filing | Ongoing | Intramuscular | COVID-19 |
| Invivyd Inc. | ADG20 - (EVADE) | COVID-19 (prevention) | Phase 2/3 | Data Released | Intramuscular | COVID-19 |
| Invivyd Inc. | ADG 20 | Healthy Volunteers | Phase 2/3 | Data Released | Intravenous | N/A |
| IO Biotech Inc. | IO102-IO103 - (IOB-032) | Squamous cell carcinoma of the head and neck (SCCHN) | Phase 2 | Trial Completed | Intravenous | Oncology |
| IO Biotech Inc. | IO102-IO103 with pembrolizumab - (basket trial) | Metastatic solid tumors | Phase 2 | Enrollment Conclusion | Intravenous | Oncology |
| IO Biotech Inc. | IO102-IO103 in combination with pembrolizumab - (IOB-022) | Non-small cell lung cancer (NSCLC) | Phase 2 | Data Released | Intravenous | Oncology |